|
|
|
|
| LEADER |
03603nmm a2200337 u 4500 |
| 001 |
EB002015790 |
| 003 |
EBX01000000000000001178689 |
| 005 |
00000000000000.0 |
| 007 |
cr||||||||||||||||||||| |
| 008 |
220613 ||| eng |
| 020 |
|
|
|a 9783030887193
|
| 100 |
1 |
|
|a Williams III, Robert O.
|e [editor]
|
| 245 |
0 |
0 |
|a Formulating Poorly Water Soluble Drugs
|h Elektronische Ressource
|c edited by Robert O. Williams III, Daniel A. Davis Jr., Dave A. Miller
|
| 250 |
|
|
|a 3rd ed. 2022
|
| 260 |
|
|
|a Cham
|b Springer International Publishing
|c 2022, 2022
|
| 300 |
|
|
|a XII, 693 p. 280 illus., 138 illus. in color
|b online resource
|
| 505 |
0 |
|
|a Route-Specific Challenges in the Delivery of Poorly Water-Soluble Drugs -- Optimizing the Formulation of Poorly Water-Soluble Drugs -- Solid-State Techniques for Improving Solubility -- Mechanical Particle-Size Reduction Techniques -- Co-solvent and Complexation Systems -- Injectable Formulations of Poorly Water-Soluble Drugs -- Lipid-Based Formulations -- Structured Development Approach for Amorphous Systems -- Melt Extrusion -- Spray-Drying Technology -- Pharmaceutical Cryogenic Technologies -- Precipitation Technologies for Nanoparticle Production -- Emerging Technologies to Increase the Bioavailability of Poorly Water-Soluble Drugs -- Scientific and Regulatory Considerations for Development and Commercialization of Poorly Water-Soluble Drugs
|
| 653 |
|
|
|a Pharmaceutical chemistry
|
| 653 |
|
|
|a Medical Biochemistry
|
| 653 |
|
|
|a Pharmaceutics
|
| 653 |
|
|
|a Pharmacology
|
| 653 |
|
|
|a Clinical biochemistry
|
| 700 |
1 |
|
|a Davis Jr., Daniel A.
|e [editor]
|
| 700 |
1 |
|
|a Miller, Dave A.
|e [editor]
|
| 041 |
0 |
7 |
|a eng
|2 ISO 639-2
|
| 989 |
|
|
|b Springer
|a Springer eBooks 2005-
|
| 490 |
0 |
|
|a AAPS Advances in the Pharmaceutical Sciences Series
|
| 028 |
5 |
0 |
|a 10.1007/978-3-030-88719-3
|
| 856 |
4 |
0 |
|u https://doi.org/10.1007/978-3-030-88719-3?nosfx=y
|x Verlag
|3 Volltext
|
| 082 |
0 |
|
|a 615.19
|
| 520 |
|
|
|a The objective of this third edition is to consolidate within a single text the most current knowledge, practical methods, and regulatory considerations pertaining to formulations development with poorly water-soluble molecules. A pharmaceutical scientist’s approach toward solubility enhancement of a poorly water-soluble molecule typically includes detailed characterization of the compound’s physiochemical properties, solid-state modifications, advanced formulation design, non-conventional process technologies, advanced analytical characterization, and specialized product performance analysis techniques. The scientist must also be aware of the unique regulatory considerations pertaining to the non-conventional approaches often utilized for poorly water-soluble drugs. One faced with the challenge of developing a drug product from a poorly soluble compound must possess at a minimum a working knowledge of each of the above mentioned facets and detailed knowledge of most. In light of the magnitude of the growing solubility problem to drug development, this is a significant burden especially when considering that knowledge in most of these areas is relatively new and continues to develop. Highlights the most recent advancements reported in the literature on technologies to improve the dissolution and bioavailability of poorly water soluble drugs Provides a comprehensive discussion of new technologies developed and recently over 40% updated new content Essential read for scientists and researchers in pharmaceutical, chemical, and agricultural industries since over 80% of newly discovered drugs are poorly water soluble
|